EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis

Yuanyuan Geng iD, Peng Liu, Min Jin, Guoyan Qi iD, Xiaoting Lin iD, Yousheng Zhang iD

Journal of Immunology Research · 2026-01 · 2026 (1)

DOI: 10.1155/jimr/3929690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, online erschienen am 29.07.2026. Verfasst von Yuanyuan Geng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Cytokines, Myasthenia Gravis, Drugs, Chinese Herbal. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Central Guidance for Local Scientific and Technological Development Funding Projects, Key Laboratory Construction Subsidy Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In order to investigate the therapeutic mechanism of Jianpiyiqi Granule in juvenile myasthenia gravis (JMG) and find the immune‐associated cytokines or signaling pathways targeted by this intervention.

Methods

(1) We extracted JMG serum samples from the sample bank of the Hebei Provincial Key Laboratory of Myasthenia Gravis before and after treatment. (2) Using Olink Immune Response Panel detects serum cytokines. Data were collated and analyzed using statistical software. Differentially expressed proteins (DEPs) were visualized using heat maps, volcano plots, and other tools. Differentially expressed cytokines were analyzed using KEGG enrichment pathway analysis to identify the relevant signaling pathways they participate in.

Results

(1) Twelve of 92 cytokines were found to be differentially expressed from 20 patients before and after treatment, namely AXIN1, CCL11, CCL13, CCL20, CCL25, CCL3, CD40, IL12B, S100A12, SIRT2, SLAMF1, and STAMBP (|log 2 FC| > 0.263; false discovery rate (FDR)‐adjusted p < 0.05). IL12B was upregulated while AXIN1, CCL11, CCL13, CCL20, CCL25, CCL3, CD40, S100A12, SIRT2, SLAMF1 and STAMBP were downregulated after treatment. Notably, three of these—CCL11, IL12B, and STAMBP—showed stronger statistical evidence, with FDR‐adjusted p < 0.01 and |log 2 FC| > 0.263. (2) The following pathways were obtained by KEGG enrichment analysis of 12 cytokines: cytokine–cytokine receptor interaction, viral protein interaction with cytokine and cytokine receptor, chemokine signaling pathway, Toll‐like receptor (TLR) signaling pathway, intestinal immune network for IgA production, IL‐17 signaling pathway, NF‐kappa B signaling pathway. (3) CCL11 and CCL20 were enriched in the IL‐17 signaling pathway. We used enzyme‐linked immunosorbent assay (ELISA) to retest additional serum samples before and after treatment from 12 JMG patients before and after treatment. The results showed a significant decrease in CCL11 and CCL20 in after‐treatment serum ( p < 0.05).

Conclusions

Drug therapy for JMG revealed 12 differentially expressed cytokines. Due to the exploratory nature and sample volume constraints, only two candidate cytokines were validated by ELISA. We found that the cytokines CCL11 and CCL20—associated with the IL‐17 signaling pathway—were downregulated after treatment. The drug therapy may inhibit MG progression by reducing the expression of IL‐17‐associated cytokines. At the same time, the drug reduced the expression of CCL3, CCL13, CCL25, and CD40, which may play a role in the abnormal proliferation of thymocytes and chronic inflammatory response at the neuromuscular junction. Future studies with multiplex assays are needed to confirm the involvement of other differentially expressed cytokines, such as SIRT2 and AXIN1, which may contribute to disease mechanisms outside the identified pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesMyasthenia GravisDrugs, Chinese HerbalHumansSignal TransductionFemaleMaleChildAdolescentGene Expression Profiling

Stichwörter der Autor:innen

cytokinemyasthenia gravissignal pathwaytreatment

Substanzen

CytokinesDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China.
  • Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China.
  • Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China.
  • School of Basic Medicine, North China University of Science and Technology, Tangshan, Hebei, China, ncst.edu.cn.
  • Faculty of Medicine and Health, The University of Melbourne, Parkville, Melbourne 3010, Victoria, Australia, unimelb.edu.au.

ORCID-Profile: Yuanyuan Geng, Guoyan Qi, Xiaoting Lin, Yousheng Zhang

Förderung

  • National Natural Science Foundation of China
  • Central Guidance for Local Scientific and Technological Development Funding Projects
  • Key Laboratory Construction Subsidy Fund Project

Zitieren

APA

Geng, Y., Liu, P., Jin, M., Qi, G., Lin, X., & Zhang, Y. (2026). Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/3929690

Vancouver

Geng Y, Liu P, Jin M, Qi G, Lin X, Zhang Y. Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/3929690

BibTeX
@article{Geng2026,
  author = {Geng, Yuanyuan and Liu, Peng and Jin, Min and Qi, Guoyan and Lin, Xiaoting and Zhang, Yousheng},
  title = {Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis},
  journal = {Journal of Immunology Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jimr/3929690}
}
Kostenlos starten →